Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
32.11 ^USD	+1.97%		-3.60%	+65.69%

05-10	Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	CI

Neoleukin Therapeutics, Inc. Announces Resignation of Holly Vance as General Counsel and Corporate Secretary

November 19, 2021 at 08:31 am

On November?17, 2021, Neoleukin Therapeutics, Inc. (the ?Company?) received notice from Holly Vance of her intention to resign as the Company?s General Counsel and Corporate Secretary to pursue another opportunity.

Latest news about Neurogene Inc.

Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	05-07	CI
Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	04-29	MT
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
William Blair Initiates Neurogene With Outperform Rating	03-21	MT
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
North American Morning Briefing : Inflation -2-	03-15	DJ
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	03-04	CI
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	02-21	CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	01-17	CI
Neurogene Names Julie Jordan as Chief Medical Officer	01-16	MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	01-16	CI
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	01-08	MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	01-05	MT
Neurogene Announces Business Update and 2024 Outlook	01-05	CI
Neurogene Completes Merger With Neoleukin Therapeutics	12-19	MT
Neoleukin Therapeutics, Inc.(NasdaqCM:NLTX) dropped from NASDAQ Composite Index	12-18	CI
Neurogene Inc. announced that it has received $95 million in funding from a group of investors	12-17	CI
Neurogene Inc. completed the acquisition of Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $120 million in a reverse merger transaction.	12-17	CI
Neoleukin Therapeutics Board Approves Reverse Stock Split, Increase in Authorized Common Stock Capital to 500 Million	12-15	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sector Update: Health Care Stocks Rise Slightly Late Afternoon	23-09-22	MT
Sector Update: Health Care Stocks Mixed Friday Afternoon	23-09-22	MT
Neoleukin Therapeutics Board Approves 1-for-5 Reverse Stock Split	23-09-22	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Chart Neurogene Inc.

Duration

Period

More charts

Company Profile

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Goldman Sachs Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.11 USD

Average target price

51.25 USD

Spread / Average Target

+59.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROGENE INC.	+65.69%	413M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research